These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1124318)

  • 1. Thromboembolic complications of oral contraceptive therapy.
    Ambrus JL; Mink IB; Courey NG; Niswander K; Moore RH; Ambrus CM; Lillie MA
    Res Commun Chem Pathol Pharmacol; 1975 Jan; 10(1):197-200. PubMed ID: 1124318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progestational agents and blood coagulation. VII. Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.
    Ambrus JL; Mink IB; Courey NG; Niswander K; Moore RH; Ambrus CM; Lillie MA
    Am J Obstet Gynecol; 1976 Aug; 125(8):1057-62. PubMed ID: 133615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of oral estrogen-progestin compounds on blood coagulation factors.
    Hodges RM
    Int J Fertil; 1968; 13(4):349-53. PubMed ID: 5700392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
    Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulatory effects of estrogen.
    Kushner S
    Ohio State Med J; 1970 Oct; 66(10):1016-21. PubMed ID: 4918754
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of oral contraceptive estrogen on blood coagulation and fibrinolysis.
    Hedlin AM
    Thromb Diath Haemorrh; 1975 Apr; 33(2):370-8. PubMed ID: 1138426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Statement on the thromboembolic risk while taking oral contraceptives].
    Rozenbaum H
    Therapeutique; 1970 Apr; 46(4):439-41. PubMed ID: 5427202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hormonal contraceptive therapy and thromboembolic disease].
    Narvaiza MJ; Hernández M; Arrizabalaga B; Solana JM; Pérez Val JA; Rocha E
    Rev Med Univ Navarra; 1980 Dec; 24(4):49-53. PubMed ID: 7038816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative metabolic effects of oral contraceptive preparations containing different progestagens. Effects of desogestrel + ethinylestradiol on the haemostatic balance.
    Rákóczi I; Gerö G; Demeter J; Gáti I
    Arzneimittelforschung; 1985; 35(3):630-3. PubMed ID: 3158320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hormonal contraception and blood coagulation disorders].
    Schander K; Plotz EJ
    Med Klin; 1974 Feb; 69(7):265-71. PubMed ID: 4596111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood viscosity and thrombosis: clinical considerations.
    Smith BD; La Celle PL
    Prog Hemost Thromb; 1982; 6():179-201. PubMed ID: 6762612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of hypercoagulability in venous and arterial thrombosis.
    Wessler S
    Cardiovasc Clin; 1971; 3(1):1-16. PubMed ID: 4944368
    [No Abstract]   [Full Text] [Related]  

  • 15. [Side effects of oral contraceptives].
    Böttiger LE; Westerholm B
    Lakartidningen; 1971 Sep; 68(39):4371-8. PubMed ID: 5130326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptives and deep venous thrombosis with pulmonary embolism.
    Bouché RT; Medawar SJ; Dockery GL
    J Foot Surg; 1982; 21(4):297-301. PubMed ID: 7186920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal contraception and thromboembolic disease: effects of the oral contraceptives on hemostatic mechanisms. A review of the literature.
    Dugdale M; Masi AT
    J Chronic Dis; 1971 Mar; 23(10):775-90. PubMed ID: 4933752
    [No Abstract]   [Full Text] [Related]  

  • 19. Changes in spontaneous fibrinolytic activity during use of oral contraceptives.
    Hedlin AM; Monkhouse FC
    Obstet Gynecol; 1971 Feb; 37(2):225-32. PubMed ID: 5539358
    [No Abstract]   [Full Text] [Related]  

  • 20. [Changes in blood coagulation during hormonal contraception].
    von Hugo R; Lenz A; Hafter R
    Gynakol Rundsch; 1985; 25 Suppl 2():138-41. PubMed ID: 4093018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.